

## ORIGINAL ARTICLES

# Detecting EGFR mutations (L858R, T790M) using allele specific multiplex sequencing: A comparison with Pyrosequencing and TruSeq

Dilanthi Vinayagamoorthy<sup>1</sup>, Jennifer Walsh<sup>1</sup>, Kierra Gipson<sup>1</sup>, Fei Ye<sup>3</sup>, Minghao Zhong<sup>3</sup>, Qin Dahui<sup>2</sup>, Thuraiayah Vinayagamoorthy\*<sup>1</sup>

<sup>1</sup>Select MultiGEN Diagnostics, Greensboro, NC, United States

<sup>2</sup>Molecular Diagnostic Lab, Moffitt Cancer Center, FL, United States

<sup>3</sup>Westchester Medical Center, Valhalla, NY, United States

**Received:** December 23, 2019

**Accepted:** February 16, 2020

**Online Published:** March 6, 2020

**DOI:** 10.5430/jst.v10n1p19

**URL:** <https://doi.org/10.5430/jst.v10n1p19>

## ABSTRACT

We are presenting an evaluation of Allele Specific Multiplex Sequencing (ASMS) to detect two EGFR somatic mutations (L858R, T790M). Late stage lung cancer samples were tested for both EGFR mutations and were compared to either pyrosequencing or TruSeq. The analytical lower limit of detection (LLOD) for the ASMS-L858R assay was found to be 36 copies, and 72 copies for the ASMS-T790M assay. The forty-one FFPE samples that were tested for T790M showed 100% concordance with the respective comparative method. The forty-five FFPE samples tested previously by Truseq for L858R showed 100% concordance with ASMS. Out of the twenty L858R samples previously tested by pyrosequencing, there was 95% concordance with ASMS. Additionally, twenty-one normal blood samples were tested by ASMS were found to be negative for L858R and T790M. In conclusion, the detection of L858R and T790M by ASMS are in acceptable concordance with both pyrosequencing and TruSeq in detecting EGFR mutations from late stage lung cancer. Further, ASMS was able to detect EGFR (L858R) with 10 picograms (3 copies gDNA) of FFPE extracted DNA, and hence could be used to detect mutations from samples carrying low copy numbers.

**Key Words:** ASMS, EGFR, L858R, T790M, Lung cancer

## 1. INTRODUCTION

Targeted chemotherapy is one of the therapeutic modalities used in the management of late stage cancers. Late stage non-small cell lung cancer (NSCLC) is treated with specific targeted chemotherapy subject to detecting specific Epidermal Growth Factor receptor (EGFR) somatic mutations.<sup>[1,2]</sup> Two of the 'actionable' EGFR mutations are L858R and T790M, both of which are associated with lung cancer.<sup>[3,4]</sup> These markers are routinely tested using DNA extracted from FFPE samples, and use of specific targeted chemotherapies

has shown clinical utility. Having documented clinical utility in stage IV cancers, studies are underway to explore use of targeted chemotherapies in early stage cancers (< stage IIIa, IIIb, II). A previous report shows that detection of Braf p. V600E/K mutations was significantly higher using ASMS compared to two of the presently used technologies. Further, early stage cancers tend to have less cancer burden than stage IV cancers, and hence may carry a fewer number of copies of targeted chemotherapy specific somatic mutations. Therefore, detection of actionable mutations in early stage

\*Correspondence: Thuraiayah Vinayagamoorthy; Email: moorthy@multigen-diagnostics.com; Address: Select MultiGEN Diagnostics, Greensboro, NC 27405, United States.

cancers may require assays that are more sensitive than what is currently available.

Prior to engagement in detecting EGFR L858R and T790M in early stage cancers, the assay requires clinical validation. This study presents results of a clinical validation of detecting EGFR L858R and T790M mutations using Allele specific Multiplex Sequencing (ASMS) technology, and comparison to pyrosequencing and TruSeq.<sup>[6-9]</sup> Further, clinical lower limit of detection was determined using serially diluted positive EGFR L858R and T790M biopsy samples.

## 2. MATERIALS AND METHODS

### 2.1 Samples

The study included DNA controls (Horizon Discoveries UK), twenty-one blood samples from asymptomatic normal population and one hundred and six de-identified late stage lung cancer DNA extracts from FFPE samples.

### 2.2 Method

DNeasy Blood (Qiagen, USA) was used according to manufacturer’s instructions to obtain DNA from 1 ml of blood. Ten ul of the DNA extract was used per PCR reaction. Amplification and cycle sequencing were performed separately for T790M and L858R, according to manufacturer’s instructions (MultiGEN Diagnostics Inc, USA).

**Table 1.** ASMS EGFR (T790M) Lower limit of detection

Serial dilution	Copies of EGFR-T790M/Rxn	Results
Stock solution	5ng/ul	N/T
1:10	7,250	T790M Positive
1:100	725	T790M Positive
1:1000	73	T790M Positive
1:10000	7	T790M Negative
1:100000	<1.0	T790M Negative
Negative	0	Negative

**Table 2.** ASMS EGFR ( L858R) Lower limit of detection

Serial dilution	Copies of EGFR-L858R/Rxn	Results
Stock solution	5ng/ul	
Original	730	L858R Positive
1:2	365	L858R Positive
1:4	182	L858R Positive
1:10	73	L858R Positive
1:20	36	L858R Positive
1:40	18	L858R Negative
Negative	0	Negative

## 3. RESULTS AND DISCUSSION

### 3.1 Sensitivity

Lower limit of detection of L858R and T790M was determined using hgDNA from human cell line. (Horizon Discoveries Cambridge, UK.). Using serial dilutions of the human cell line extracted DNA stock solution (5ug/ul), the lower limit of detection was 36 copies for L858R and 73 copies for T790M (see Tables 1, 2).

**Table 3.** Primer Specificity of ASMS for detection of EGFR L858R

Template	Sequencing Primer	Electropherogram
Mutant	Mutant-L858R	Mutant signal
Mutant	Wild-L858L	Negative
Wild	Wild-L858L	Wild type signal
Wild	Mutant-L858R	Negative
Wild /Mutant	Mutant-L858R & Wild-L858L	Mutant & Wild type signal

**Table 4.** Primer Specificity of ASMS for detection of EGFR T790M

Template	Squencing primer	Electropherogram
Mutant	Mutant-T790M	Mutant signal
Mutant	Wild-T790T	Negative
Wild	Wild-T790T	Wild type signal
Wild	Mutant-T790M	Negative
Wild/Mutant	Mutant-T790M & Wild-T790T	Mutant & Wild type signal

### 3.2 Specificity


#### 3.2.1 L858R and T790M

Using plasmid controls (Integrated DNA Technologies, USA), specificities of the sequencing primers were determined. L858R and T790M were tested for specificity separately. The mutant sequencing primer and the wild type sequencing primer with their respective control plasmid templates generated expected nucleotide sequences (see Tables 3, 4). The mutant sequencing primer with wild type template, and wild type sequencing primer with mutant plasmid template did not generate a nucleotide sequence. When both sequencing primers were added into a reaction with wild type controls, only wild type sequence was generated (see Figure 1, 2). When both sequencing primers were added into a reaction with mutant plasmid and wild type controls, this generated two sequences; one from the mutant and the other from the wild type at the respective locus (see Figure 3, 4). In addition, all twenty-one normal blood samples that were tested for EGFR L858R and T790M were negative for mutation (see Table 5).


**Table 5.** Comparison of ASMS ( EGFR T790M and L858R) with Pyrosequencing and TruSeq

Samples			Results			
Marker	Type	Number of samples tested	Allele Status	ASMS	Pyrosequencing	TruSeq
T790M	Normal blood	21	T790M	0	NT	NT
			Negative	21	NT	NT
	FFPE	3	T790M	0	0	–
			Negative	3	3	–
L858R	Normal blood	21	T790M	7	–	7
			Negative	31	–	31
	FFPE	20	L858R	4	3	–
			Negative	16	17	–
FFPE	45	L858R	3	–	3	
		Negative	42	–	42	
Total		148				

Note. NT= Not Tested; NA= Not applicable



**Figure 1.** Electropherogram of a L858R negative FFPE sample



**Figure 2.** Electropherogram of a T790M negative FFPE sample


**Table 6.** Serial dilution of FFPE sample EGFR L858R

Amount of DNA/sample	No. of mutant copies/sample	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5	Sample 6
1ng	300	M/W	M/W	M/W	M/W	M/W	M/W
0.1ng	30	M/W	M/W	M/W	M/W	M/W	M/W
0.01ng	3	Neg	Neg	Neg	M/W	Neg	M/W
0.001ng	0	Neg	Neg	Neg	Neg	Neg	Neg
0.0001ng	0	Neg	Neg	Neg	Neg	Neg	Neg
0.00001ng	0	Neg	Neg	Neg	Neg	NT	Neg
0.000001ng		Neg	NT	NT	NT	NT	NT
Neg		Neg	Neg	Neg	Neg	Neg	Neg


**Table 7.** Serial dilution of FFPE sample EGFR T790M

Amount of DNA/sample	No. of mutant copies/sample	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5	Sample 6
1ng	300	W	W	W	W	W	W
0.1ng	30	W	Neg	W	Neg	W	W
0.01ng	3	Neg	Neg	Neg	Neg	W	W
0.001ng	0	Neg	Neg	Neg	Neg	Neg	Neg
0.0001ng	0	Neg	Neg	Neg	Neg	Neg	Neg
0.00001ng	0	Neg	Neg	Neg	Neg	Neg	Neg
0.000001ng		NT	NT	NT	NT	NT	NT

Note. M=Mutant allele; W=Wild-type allele; NT= Not Tested; Neg= Negative \*1ng of genomic DNA= approximately 300 copies of mutant allele, given 100% tumor content



**Figure 3.** Electropherogram of a L858R positive FFPE sample



**Figure 4.** Electropherogram of a T790M positive FFPE sample

### 3.2.2 Comparison detection of EGFR L858R, T790M using FFPE samples

Out of the forty-one samples that were tested for T790M, three were tested by pyrosequencing, all three were negative by both pyrosequencing and ASMS. Of the remaining thirty-eight samples that were compared with TruSeq, the seven positives and thirty-one negatives were all in 100% concordance with ASMS (see Table 5). Of the twenty samples tested by pyrosequencing for L858R, all but one sample were in concordance with ASMS, and of the forty-five samples tested by TruSeq for L858R, all the three positives and forty-two negative samples were in concordance with ASMS. Presently, the selection of targeted chemotherapy for late stage cancers has been based on molecular diagnostics platforms that were either developed for the detection of pathogens (e.g. Real time PCR) or for detecting germ line mutations (NGS). Clinical samples used for both real time PCR and NGS carry overwhelming copies of the intended molecular target, hence detection of intended molecular targets have been within the limits of respective technologies. However, detection of somatic mutations in early stages of cancer is becoming one of the main strategies for successful treatment of cancer, and this requires molecular technologies that could detect samples carrying low copy numbers. Further, incidence of somatic mutations in other cancer types such as ovarian, esophageal, etc. have not been reported, and may warrant re-evaluation of actionable somatic mutations. What is required for detection of mutations in early cancer stages is a molecular platform that could detect respective somatic mutations in samples carrying low copies of the

mutant allele.

In addition to having both wild and the mutant allele in the same assay, ASMS technology could also accommodate more than one target, and hence becomes cost effective by testing multiple targets. Presently there are three DNA sequencing platforms, Sanger sequencing, pyrosequencing and next generation sequencing (e.g. TruSeq). In conventional Sanger sequencing/capillary electrophoresis, the florescent signal from a sample with low mutant copies is suppressed by the wild type signal such that the mutant signal may be indistinguishable from the noise, and thus only could be applied to samples with higher tumor content. ASMS technology separates the mutant signal from that of the wild type, hence the mutation can be detected with low copy numbers. NGS technologies have eleven enzyme mediated steps, such that cumulative errors could affect the accuracy. In order to minimize these errors NGS needs high copies of mutant in the sample. ASMS is an amplicon/sequencing technology and is determined by two primers in the PCR reaction and one sequencing primer, thus reducing the chance of error. In pyrosequencing, interpreting peak heights is subject to experienced technical expertise, and therefore it is subjective. ASMS generates an electropherogram specific to the mutation of interest and can be analyzed by software, thus is not dependent on subjective interpretation. Further, we reported comparison of ASMS with other molecular technologies.<sup>[10]</sup>

In summary, the study shows that ASMS is in concordance with pyrosequencing and TruSeq in detecting actionable EGFR driver mutations from clinical samples. Further,

ASMS can detect somatic mutation alleles at very low copy numbers. This data suggests that ASMS is suitable to detect actionable somatic mutations in early stages of cancer, and suitable to re-evaluate incidence of actionable somatic mutations in cancers where incidence of these mutations has not

been reported.

## CONFLICTS OF INTEREST DISCLOSURE

Thuraiayah Vinayagamoorthy is President of MultiGEN Diagnostics, Inc.

## REFERENCES

- [1] Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. *Mod Pathol.* 2008 May; 21 Suppl 2: S16-22. PMID:18437168. <https://doi.org/10.1038/modpathol.3801018>
- [2] Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A.* 2004 Sep 7;101(36):13306-11. PMID:15329413. <https://doi.org/10.1073/pnas.0405220101>
- [3] Kenneth S, Thress Roz Brant T, Hedley Carr cSimon Deardend Suzanne Jenkins e Helen Brownd Tracey Hammettf Mireille CantarinigJ, Carl Barretta. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. *Lung Cancer.* 2015 December; 90(3): 509-515. PMID:26494259. <https://doi.org/10.1016/j.lungcan.2015.10.004>
- [4] Sandrine Dufort, Marie-Jeanne Richard, Sylvie Lantuejoul, et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC *J Exp Clin Cancer Res.* 2011; 30(1): 57. PMID:21575212. <https://doi.org/10.1186/1756-9966-30-57>
- [5] Vinayagamoorthy T, Zhang D, Ye F, Vinayagamoorthy D, Hodgkinson R. Can detection of Braf p.V600E mutation be improved? Comparison of allele specific multiplex sequencing to present tests. *Journal of Solid Tumors.* 2017; 7(2): 14. <https://doi.org/10.5430/jst.v7n2p14>
- [6] Sandrine Dufort, Marie-Jeanne Richard, Sylvie Lantuejoul, et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. *J Exp Clin Cancer Res.* 2011; 30(1): 57. <https://doi.org/10.1056/NEJMoA1709684>
- [7] Gillian Ellison, Guanshan Zhu, Alexandros Moulis, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. *J Clin Pathol.* 2013; 66:79-89. PMID:23172555. <https://doi.org/10.1136/jclinpath-2012-201194>
- [8] Martínez-Carretero C, Pascual FI, Rus A, et al. Detection of EGFR mutations in patients with non-small cell lung cancer by high resolution melting. Comparison with other methods *Clin Chem Lab Med.* 2017 Oct 26; 55(12): 1970-1978. PMID:28432840. <https://doi.org/10.1515/cc1m-2016-0353>
- [9] Hee JK, Seo YO, Wan SK, et al. Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. *Oncol Lett.* 2013 Jan; 5(1): 271-276. PMID:23255934. <https://doi.org/10.3892/ol.2012.950>
- [10] Moorthy, Thurai. An algorithm to evaluate the efficacy of detecting somatic mutations. *J Solid Tumors.* 2018; 8(2): 25. <https://doi.org/10.5430/jst.v8n2p25>